Refine your search

Content type
Tags
Firm name
Author
Jurisdiction
Language

866 results found

Commentary
Ask Lexy

Smart & Biggar | Canada | 17 Nov 2021

Federal Court remits Belsomra CSP timing refusal for redetermination

In August 2019, the minister of health denied Merck's application for a certificate of supplementary protection (CSP) for Canadian Patent No. 2,670,892 relating to the drug suvorexant (Merck's Belsomra). The Federal Court recently set aside the minister's decision and remitted Merck's CSP application for redetermination. This decision adds to the Court's growing CSP jurisprudence.
Article
Ask Lexy

Bereskin & Parr LLP | Canada | 23 Sep 2021

Another positive outcome for diagnostic methods from the patent Appeal Board

The recent Patent Appeal Board (PAB) decision in Re Antibodyshop A/S (2021 CACP 35), further indicates the PAB's willingness to find valid diagnostic…
Commentary
Ask Lexy

Smart & Biggar | Canada | 8 Sep 2021

Federal Court of Appeal remits pricing decision on Alexion's Soliris to Patented Medicine Prices Review Board

In 2017 the Patented Medicine Prices Review Board (the board) decided that Alexion's Soliris (eculizumab) was sold at an excessive price. However, the Federal Court of Appeal recently set aside the Federal Court's decision to dismiss Alexion's application for judicial review and remitted the matter to the board for redetermination, directing it "to examine the evidence, interpret the......
Analysis PRO
Ask Lexy

Lexology PRO | Australia, Canada, European Union, etc. | 17 Aug 2021

Artificial inventors: key lessons from recent AI patent decisions

A look at the DABUS AI patent application decisions and what they mean for artificial inventorship in key jurisdictions around the globe.
Article
Ask Lexy

McDermott Will & Emery | USA | 17 Jun 2021

10th Circuit Falls into Line on Exceptionality Doctrine in Lanham Act Cases

Addressing whether the term “exceptional case” in the Patent Act differs in meaning from the same term used in the Lanham Act, the US Court of…
Article
Ask Lexy

Gowling WLG | Canada | 21 Sep 2020

Electronic signature considerations for Patent practice

In the wake of the COVID-19 pandemic, many people are working from home, making it more difficult than usual to get handwritten signatures. Here are…
Article
Ask Lexy

Fasken | Canada | 1 Apr 2020

COVID-19 Developments in Pharmaceutical Regulation

On March 25, 2020, the Federal Government enacted the COVID-19 Emergency Response Act. This Act amends the Food and Drugs Act and grants the Governor…
Article
Ask Lexy

Bereskin & Parr LLP | Canada | 26 Mar 2020

Patent Act Amended as Part of Canada’s Response to COVID-19 Pandemic

After courthouse closures and suspensions, the Canadian Intellectual Property Office's suspension of Patent Act, Trademarks Act and Industrial Design…
Article
Ask Lexy

Gowling WLG | Canada | 26 Mar 2020

COVID-19 Emergency Response Act: Amendments to the Patent Act

After lengthy deliberations, the Federal Government has passed an aid bill in response to the COVID-19 pandemic (COVID-19 Emergency Response Act). The…
Article
Ask Lexy

Bereskin & Parr LLP | Canada | 25 Mar 2020

Des modifications à la Loi sur les brevets en réaction à la pandémie de COVID-19

Après la suspension des activités judiciaires et la fermeture des palais de justice, la suspension par l’Office de la propriété intellectuelle du…
Previous page 1 2 3 ...